Rochester, NY 6/8/2009 9:00:36 PM
WhisperfromWallstreet Morning Movers - SPONGETECH DELIVERY,SPNG.OB - Micromet, Inc.,MITI - Keryx Biopharmaceuticals, Inc.,KERX
SpongeTech® Delivery Systems, Inc. - Micromet, Inc. - Keryx Biopharmaceuticals, Inc.
WhisperfromWallstreet Morning Movers - SPONGETECH DELIVERY,SPNG.OB - Micromet, Inc.,MITI - Keryx Biopharmaceuticals, Inc.,KERX
SPONGETECH DELIVERY,SPNG.OB
WhisperFromWallStreet Alert
April 26 .0148
500% gain
SpongeTech® Delivery Systems, Inc., America’s Cleaning Company, is pleased to announced that the Company will be presenting at Noble Financial's Fifth Annual Investor Conference, a two day conference from June 8-9, 2009, at the Hard Rock Hotel in Hollywood, Florida. SpongeTech®'s CEO, Michael Metter, and COO, Steven Moskowitz are scheduled to present SpongeTech®, America’s Cleaning Company, at 9:15 am EST, Monday June 8, 2009 and will host a question and answer session after the presentation.
SpongeTech®’s COO Steven Moskowitz said, "As we begin our 2010 fiscal year, this conference give us the opportunity to present our Company to many portfolio managers, analysts and potential investors and to share our growth strategy and recent
ABOUT
SpongeTech Delivery Systems, Inc. designs, produces, and markets unique lines of reusable cleaning products for car care, child care, home care, and pet care usages. These sponge-like products utilize SpongeTech's proprietary, patent (and patent-pending) technologies, and other technologies involving hydrophilic (liquid absorbing) foam, polyurethane matrices, or other ingredients. The company's sponge-like products are pre-loaded with specially formulated ingredients, such as soap, conditioner, and/or wax that are released when the sponge is soaked and applied to a surface with minimal pressure. SpongeTech Delivery Systems is exploring additional applications for its technology in the health, beauty, and medical markets. It plans to globally brand its company as America's Cleaning Company. The company was founded in 1999 and is based in New York, New York.
---
If you are viewing this press release you are obviously interested in making money in the stock market. In today’s market investors need every tool available. WhisperfromWallStreet.com sends FREE alerts to our subscribers on stocks that we feel are ready to move within hours or days. So far in 2009 we have sent 36 stock alerts to our clients and the average price gain has been 88%. To add additional profits to your portfolio please take a minute and sign up for our free alerts. There is no risk to you and you will see just how accurate we are in our alerts.
Investors sign up for our FREE alerts at http://whisperfromwallstreet.com
---
Micromet, Inc.,MITI
Micromet, Inc., a biopharmaceutical company, engages in the development and sale of antibodies for the treatment of cancer, inflammation, and autoimmune diseases. The company’s products under development pipeline using BiTE antibody technology platform include MT103, which is evaluated in a Phase II clinical trial for the treatment of acute lymphoblastic leukemia and in a Phase I clinical trial for the treatment of non-Hodgkin’s lymphoma; and MT110 that is tested in a Phase I clinical trial for the treatment of patients with solid tumors. Its products also include adecatumumab (MT201), a recombinant human monoclonal antibody in Phase Ib clinical trial to treat patients with metastatic breast cancer; and MT293, a humanized anti-metastatic and anti-angiogenic monoclonal antibody in a Phase I clinical trial for the treatment of patients with solid tumors. In addition, the company’s pre-clinical stage products include MT203, a human antibody to treat rheumatoid arthritis, asthma, psoriasis, and multiple sclerosis; MT228, a product for melanoma; MT204, a humanized antibody to treat rheumatoid arthritis, asthma, acute transplant rejection, uveitis, psoriasis, and multiple sclerosis; MT111 that binds to carcinoembryonic antigen, which is expressed in various solid tumors, including colorectal carcinoma, gastric carcinoma, lung adenocarcinoma, mucinous ovarian carcinoma, and endometrial adenocarcinoma; MCSP BiTE antibody to treat melanoma; CD33 BiTE antibody to treat acute myelogenic lymphoma; HER2 BiTE antibody to treat breast cancer; and EGFR BiTE antibody to treat solid tumors.
Last Trade: 5.53
Day's Range: 5.40 - 6.00
52wk Range: 2.25 - 7.74
Volume: 630,764
---
Keryx Biopharmaceuticals, Inc.,KERX
Keryx Biopharma announces positive Phase 2 data for Zerenex Co announces results of the Phase 2 study of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on thrice weekly hemodialysis. The study was a multicenter, open-label clinical trial, which enrolled 55 patients. The top line efficacy and safety results from this Phase 2 study were submitted to the FDA, and discussed at a recent face to face meeting with the Division of Cardiovascular and Renal Drug Products. The FDA also reviewed the final reports for the 90-day rat and 16-week canine toxicology studies. The FDA indicated that the results of the Phase 2 study and the toxicology studies were adequate to support entry into a Phase 3 program. Keryx is in the process of finalizing the Phase 3 program in consultation with the FDA. Co says "The promising safety and efficacy profile of Zerenex indicates that there is significant market potential for the drug in the phosphate binder space."
Last Trade: 1.39
Day's Range: 1.35 - 1.44
52wk Range: 0.09 - 1.45
Volume: 2,148,393
----
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com
